| Followers | 28 |
| Posts | 5011 |
| Boards Moderated | 0 |
| Alias Born | 09/22/2006 |
Saturday, December 13, 2008 1:27:37 AM
Since Cheetah was unveiled, Dr. Lim has stated consistently that they intend to use other income streams to finance their independent efforts to bring it to fruition. Your opinion that they can't do it is not based on any known facts at this point in time. I grant you that it is a potentially difficult proposition, but to say they can't overcome the hurdles is mere speculation. For now I'll give Dr. Lim the edge.
-Fritz
-Fritz
The more you know, the less you don't know.
Recent HALO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 08:06:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 09:13:42 PM
- Halozyme signs licensing deal with Vertex for drug delivery technology • IH Market News • 04/07/2026 02:11:29 PM
- Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology • PR Newswire (US) • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:29:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:28:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 10:35:07 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/23/2026 08:16:26 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/23/2026 08:13:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/23/2026 08:11:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 12:32:00 PM
- Halozyme Appoints David Ramsay as Interim Chief Financial Officer • PR Newswire (US) • 03/12/2026 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/10/2026 08:05:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/09/2026 08:18:04 PM
- U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma • PR Newswire (US) • 03/06/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 11:56:16 PM
- Halozyme to Participate in Upcoming Investor Conferences • PR Newswire (US) • 02/25/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 11:19:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 11:16:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 11:12:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 11:53:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 11:52:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 11:51:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 09:04:55 PM
- HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE • PR Newswire (US) • 02/17/2026 09:01:00 PM
